VENTRICULAR ASSIST DEVICE SERVICES BUSINESS PLAN

I. Executive Summary

Company Description

VAD Care Partners (name chosen to signal Ventricular Assist Device specialization and coordinated care) is a 2026-launch clinical services company operating in the cardiac surgery and digital health sector. We provide outsourced Ventricular Assist Device programs to regional hospitals across the United States, supplying specialized surgeons, program coordinators, device management, and a proprietary telehealth platform that manages patients from the operating room through long-term at-home care. Our core products are team-based clinical services, program implementation, and remote-monitoring software that together remove the capital and operational burden of building an in-house VAD program.

We run program setup, credentialing, perioperative staffing, and longitudinal remote care so hospitals can offer elite VAD therapy without owning the program. Our differentiators are a turnkey clinical team, regulatory-compliance workflows, and an integrated telehealth platform designed for VAD-specific monitoring and patient quality-of-life metrics. Target customers are regional medical centers and community hospitals seeking tertiary cardiac services. Short-term goals are to launch initial programs in 2026 and prove clinical outcomes; long-term goals are national scale and measurable reductions in readmissions and time-to-therapy.

Problem

Advanced heart failure patients who fail medical therapy often need ventricular assist devices (VADs) but many regional hospitals cannot offer them because they lack the >$250,000 initial capital and the specialized staff—Cardiothoracic Surgeons and VAD Coordinators—required to start and sustain a program.

Hospitals face a continuous 24/7 clinical burden and complex regulatory compliance, which raises on-call costs, creates operational risk, and deters mid-sized facilities from expanding cardiac service lines; the result is geographic disparities and limited patient access to life-saving VAD care.

Our outsourced VAD program, launching in 2026 from a major medical hub, fills this gap by delivering specialized surgeons, coordinators, and a telehealth platform so regional centers can provide elite cardiac care without the capital and operational burdens of an in-house program.

Solution

Regional hospitals lack the specialized teams, infrastructure, and CMS-certified processes to offer ventricular assist device (VAD) therapy, forcing advanced heart-failure patients to travel for care and delaying treatment. Our business delivers a turnkey VAD program that brings full on-site VAD care to partner hospitals, removing the need for hospitals to build and staff programs themselves.

We supply on-site implantation and perioperative teams, including 2 Cardiothoracic Surgeons and 2 Perfusionists in 2026, proprietary telehealth for 24/7 post-discharge monitoring, device procurement and inventory logistics, regulatory reporting and certification support, and long-term outpatient VAD management to expand access and relieve hospital resource strain.

Mission Statement

Our mission is to democratize access to life-saving advanced heart failure therapies by empowering regional hospitals with elite surgical expertise and integrated clinical management. We commit to improving patient outcomes through specialized care, innovative technology, and a seamless continuum of support from hospital to home. We measure success by faster access, better survival, and sustained quality of life for patients in underserved communities.

Key Success Factors

Success depends on clinical talent, technology, partnerships, operational efficiency, and financial strength.

• Recruit and retain 10 cardiothoracic surgeons by 2030
• Proprietary telehealth platform and clinical protocols that improve outcomes and reduce readmissions
• Partnerships with hospital C-suite and VAD manufacturers providing a steady referral pipeline
• Target 85% surgeon capacity utilization by Year 5 to drive throughput and margins
• Robust financial model delivering rapid breakeven and high profitability to fund continuous innovation

Financial Summary

The company projects strong early revenue and rapid profitability driven by high-value procedures and recurring management fees.

Financial requirements: initial capex $645,000; minimum cash required $483,000 (Jun-26); payback 17 months; breakeven Feb-26. Anticipated return: ROE 49.77% and IRR 13.65%.

Overall outlook: rapid breakeven, scalable revenue growth, and strong long-term profitability.

Funding Requirements

We require USD 1,138,000 to fund the 2026 launch: USD 655,000 in capital expenditures and a minimum cash reserve of USD 483,000 to cover initial operating losses, hiring, and tech build-out.

Financial snapshot: First-year revenue of USD 1,709,000, breakeven in February 2026, projected revenue of USD 27,252,000 and EBITDA USD 23,573,000 by 2030; ROE 49.77%, IRR 13.65%, and a 17‑month payback on initial capital.